Daraprim
NEW YORK — The company that hiked the price of Daraprim, a drug used to treat AIDS patients, is backing off. Pharmaceutical company Turing increased the price of a drug called Daraprim from $13.50 to $750 a pill and its CEO, Martin Shkreli, quickly became the focus of public anger.Sep 23, 2015
Price being lowered on medicine that jumped from $13 to ...
wreg.com/.../price-being-lowered-on-medicine-that-jumped-from-13-to-75...
Drug Goes From $13.50 a Tablet to $750, Overnight - The ...
www.nytimes.com/.../a-huge-overnight-increase-in-a-drugs-price-raises-pro...
Sep 20, 2015 - The price of the drug, called Daraprim, a standard of care for treating a life-
In a demonstration of arbitrary pricing of medicines, pyremethamine, used to treat protozoal infections, went from $13 to $750 a pill in the US,
In a demonstration of arbitrary pricing of medicines, pyremethamine,
used to treat protozoal infections, went from $13 to $750 a pill in the
US, an over 5,000% increase, and down to $1 per pill for a new version,
all in a span of just over a month. The new $1 pill is being produced by
a small San Diego-based company called Imprimis Pharmaceuticals.
Daraprim, or branded pyremethamine, was bought from its producer by Turing Pharmaceuticals owned by a hedge fund manager Martin Shkreli, who then hiked the price to $750 becoming "the poster child for big pharmaceutical greed".
Despite widespread protest over the massive price hike of a 62-year-old off-patent drug, Shkreli failed to bring down the price after promising he would do so. Daraprim, which treats an uncommon parasitic infection, toxoplasmosis, is critical for treating immunocompromised patients of HIV/AIDS, cancer and pregnant women.
Imprimis Pharmaceuticals is a compounding pharmacy, which in the US means a company which mixes approved drug ingredients to prepare medicines based on a doctor's prescription. This three-and-a-half year old company is producing a formulation of Daraprim's active ingredients, pyremethamine and leucovorin.
The Imprimis formulation is not approved by the US Food and Drug Administration (FDA), but compounded formulations are allowed to be sold legally in the US as long as it is through a doctor's prescription. Compounding pharmacies do not need FDA approval unlike large pharma companies that mass produce drugs on complex production lines. The increasingly complicated regulations around FDA drug approval would have meant several years and millions of dollars for Imprimis and that would not have allowed it to keep the price affordable
Daraprim, or branded pyremethamine, was bought from its producer by Turing Pharmaceuticals owned by a hedge fund manager Martin Shkreli, who then hiked the price to $750 becoming "the poster child for big pharmaceutical greed".
Despite widespread protest over the massive price hike of a 62-year-old off-patent drug, Shkreli failed to bring down the price after promising he would do so. Daraprim, which treats an uncommon parasitic infection, toxoplasmosis, is critical for treating immunocompromised patients of HIV/AIDS, cancer and pregnant women.
Imprimis Pharmaceuticals is a compounding pharmacy, which in the US means a company which mixes approved drug ingredients to prepare medicines based on a doctor's prescription. This three-and-a-half year old company is producing a formulation of Daraprim's active ingredients, pyremethamine and leucovorin.
The Imprimis formulation is not approved by the US Food and Drug Administration (FDA), but compounded formulations are allowed to be sold legally in the US as long as it is through a doctor's prescription. Compounding pharmacies do not need FDA approval unlike large pharma companies that mass produce drugs on complex production lines. The increasingly complicated regulations around FDA drug approval would have meant several years and millions of dollars for Imprimis and that would not have allowed it to keep the price affordable
No comments:
Post a Comment